Literature DB >> 27152254

Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients.

Elisabeth Paramythiotou1, Christina Routsi1.   

Abstract

The incidence of gram-negative multidrug-resistant (MDR) bacterial pathogens is increasing in hospitals and particularly in the intensive care unit (ICU) setting. The clinical consequences of infections caused by MDR pathogens remain controversial. The purpose of this review is to summarize the available data concerning the impact of these infections on mortality in ICU patients. Twenty-four studies, conducted exclusively in ICU patients, were identified through PubMed search over the years 2000-2015. Bloodstream infection was the only infection examined in eight studies, respiratory infections in four and variable infections in others. Comparative data on the appropriateness of empirical antibiotic treatment were provided by only seven studies. In ten studies the presence of antimicrobial resistance was not associated with increased mortality; on the contrary, in other studies a significant impact of antibiotic resistance on mortality was found, though, sometimes, mediated by inappropriate antimicrobial treatment. Therefore, a direct association between infections due to gram-negative MDR bacteria and mortality in ICU patients cannot be confirmed. Sample size, presence of multiple confounders and other methodological issues may influence the results. These data support the need for further studies to elucidate the real impact of infections caused by resistant bacteria in ICU patients.

Entities:  

Keywords:  Critically ill patients; Gram-negative pathogens; Infections; Mortality; Multidrug resistance

Year:  2016        PMID: 27152254      PMCID: PMC4848154          DOI: 10.5492/wjccm.v5.i2.111

Source DB:  PubMed          Journal:  World J Crit Care Med        ISSN: 2220-3141


  67 in total

1.  Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients.

Authors:  Argyris Michalopoulos; Matthew E Falagas; Dimitra C Karatza; Paraskevi Alexandropoulou; Emmanuel Papadakis; Leonidas Gregorakos; George Chalevelakis; Georgios Pappas
Journal:  Am J Infect Control       Date:  2010-10-30       Impact factor: 2.918

2.  Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.

Authors:  Stephanie N Bass; Seth R Bauer; Elizabeth A Neuner; Simon W Lam
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

Review 3.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

4.  Risk factors for mortality associated with enterococcal bloodstream infections.

Authors:  L Stroud; J Edwards; L Danzing; D Culver; R Gaynes
Journal:  Infect Control Hosp Epidemiol       Date:  1996-09       Impact factor: 3.254

5.  The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia.

Authors:  Andrea L H Kwa; Jenny G H Low; Erin Lee; Asok Kurup; Huei-Leng Chee; Vincent H Tam
Journal:  Diagn Microbiol Infect Dis       Date:  2007-02-14       Impact factor: 2.803

Review 6.  Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence.

Authors:  Giannoula S Tansarli; Drosos E Karageorgopoulos; Anastasios Kapaskelis; Matthew E Falagas
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

Review 7.  Antimicrobial resistance and patient outcomes: the hazards of adjustment.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

8.  Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.

Authors:  Marya D Zilberberg; Andrew F Shorr; Scott T Micek; Cristina Vazquez-Guillamet; Marin H Kollef
Journal:  Crit Care       Date:  2014-11-21       Impact factor: 9.097

9.  Global dissemination of a multidrug resistant Escherichia coli clone.

Authors:  Nicola K Petty; Nouri L Ben Zakour; Mitchell Stanton-Cook; Elizabeth Skippington; Makrina Totsika; Brian M Forde; Minh-Duy Phan; Danilo Gomes Moriel; Kate M Peters; Mark Davies; Benjamin A Rogers; Gordon Dougan; Jesús Rodriguez-Baño; Alvaro Pascual; Johann D D Pitout; Mathew Upton; David L Paterson; Timothy R Walsh; Mark A Schembri; Scott A Beatson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-31       Impact factor: 11.205

10.  Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels.

Authors:  Håkan Hanberger; Massimo Antonelli; Martin Holmbom; Jeffrey Lipman; Peter Pickkers; Marc Leone; Jordi Rello; Yasser Sakr; Sten M Walther; Philippe Vanhems; Jean-Louis Vincent
Journal:  BMC Infect Dis       Date:  2014-09-22       Impact factor: 3.090

View more
  11 in total

1.  Surgical Antibiotic Prophylaxis and Risk for Postoperative Antibiotic-Resistant Infections.

Authors:  Margot E Cohen; Hojjat Salmasian; Jianhua Li; Jianfang Liu; Philip Zachariah; Jason D Wright; Daniel E Freedberg
Journal:  J Am Coll Surg       Date:  2017-10-10       Impact factor: 6.113

2.  Colistin Therapy, Survival and Renal Replacement Therapy in Burn Patients: A 10-Year Single-Center Cohort Study.

Authors:  Filippo Mariano; Valeria Malvasio; Daniela Risso; Nadia Depetris; Anna Pensa; Giacomo Fucale; Fabrizio Gennari; Luigi Biancone; Maurizio Stella
Journal:  Int J Gen Med       Date:  2022-05-25

3.  Direct antimicrobial susceptibility testing from positive blood culture bottles in laboratories lacking automated antimicrobial susceptibility testing systems.

Authors:  Mahadevan Kumar; S P S Shergill; Kundan Tandel; Kavita Sahai; R M Gupta
Journal:  Med J Armed Forces India       Date:  2018-12-20

4.  3D-QSAR, Molecular Docking and Molecular Dynamics Simulation of Pseudomonas aeruginosa LpxC Inhibitors.

Authors:  Ke Zuo; Li Liang; Wenyi Du; Xin Sun; Wei Liu; Xiaojun Gou; Hua Wan; Jianping Hu
Journal:  Int J Mol Sci       Date:  2017-05-06       Impact factor: 5.923

5.  Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?

Authors:  Martin Exner; Sanjay Bhattacharya; Bärbel Christiansen; Jürgen Gebel; Peter Goroncy-Bermes; Philippe Hartemann; Peter Heeg; Carola Ilschner; Axel Kramer; Elaine Larson; Wolfgang Merkens; Martin Mielke; Peter Oltmanns; Birgit Ross; Manfred Rotter; Ricarda Maria Schmithausen; Hans-Günther Sonntag; Matthias Trautmann
Journal:  GMS Hyg Infect Control       Date:  2017-04-10

6.  Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase.

Authors:  Gianluigi Franci; Veronica Folliero; Marcella Cammarota; Carla Zannella; Federica Sarno; Chiara Schiraldi; Angel R de Lera; Lucia Altucci; Massimiliano Galdiero
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

7.  The role of antimicrobial resistance on long-term mortality and quality of life in critically ill patients: a prospective longitudinal 2-year study.

Authors:  Triantafyllia Koukoubani; Demosthenes Makris; Zoe Daniil; Theoniki Paraforou; Vasiliki Tsolaki; Epaminondas Zakynthinos; John Papanikolaou
Journal:  Health Qual Life Outcomes       Date:  2021-03-03       Impact factor: 3.186

8.  Appropriateness of empiric antimicrobial therapy with imipenem/colistin in severe septic patients: observational cohort study.

Authors:  Ahlem Trifi; Sami Abdellatif; Cyrine Abdennebi; Foued Daly; Rochdi Nasri; Yosr Touil; Salah Ben Lakhal
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-11-16       Impact factor: 3.944

9.  Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.

Authors:  Andrew F Shorr; Christopher J Bruno; Zufei Zhang; Erin Jensen; Wei Gao; Hwa-Ping Feng; Jennifer A Huntington; Brian Yu; Elizabeth G Rhee; Carisa De Anda; Sumit Basu; Marin H Kollef
Journal:  Crit Care       Date:  2021-10-02       Impact factor: 9.097

10.  Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms.

Authors:  Joe Yang; Jaesh Naik; Matthew Massello; Lewis Ralph; Ryan James Dillon
Journal:  Infect Dis Ther       Date:  2022-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.